136 related articles for article (PubMed ID: 15676260)
1. [Adequate use of teicoplanin in bone and joint infections].
Senneville E; Legout L; Corroyer B; Yazdanpanah Y; Mouton Y
Med Mal Infect; 2004 Jun; 34 Suppl 1():S99-102. PubMed ID: 15676260
[No Abstract] [Full Text] [Related]
2. [Vancomycin therapy in bone and joint infections--looking into the future].
Krasin E; Goldwirth M; Otremski I
Harefuah; 2000 Jun; 138(11):994-6. PubMed ID: 10979416
[No Abstract] [Full Text] [Related]
3. [New therapeutic strategies with teicoplanin].
Carbone E; Nacinovich F; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():25-9. PubMed ID: 12481485
[TBL] [Abstract][Full Text] [Related]
4. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
[TBL] [Abstract][Full Text] [Related]
5. Appropriate oral antibiotics for bone and joint infections based on the susceptibility of clinical Staphylococcus aureus isolates.
Lee CS; Hwang JH; Lee JH; Song SK; Cho JH; Lee JH
Korean J Intern Med; 2015 Mar; 30(2):262-4. PubMed ID: 25750572
[No Abstract] [Full Text] [Related]
6. Teicoplanin in the treatment of serious infection.
Schaison G; Graninger W; Bouza E
J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline option for the treatment of bone and joint infections caused by multidrug-resistant Staphylococcus epidermidis.
Asseray N; Bemer P; Corvec S; Boutoille D; Touchais S; Navas D
Joint Bone Spine; 2012 Jan; 79(1):97-9. PubMed ID: 21816648
[No Abstract] [Full Text] [Related]
8. Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study.
Malandain D; Dinh A; Ferry T; Touchais S; Lustig S; Laurent F; Corvec S; Bémer P; Asseray N; Boutoille D
Int J Antimicrob Agents; 2017 Aug; 50(2):277-280. PubMed ID: 28689872
[No Abstract] [Full Text] [Related]
9. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
Nathwani D; Barlow GD; Ajdukiewicz K; Gray K; Morrison J; Clift B; France AJ; Davey P
J Antimicrob Chemother; 2003 Feb; 51(2):391-6. PubMed ID: 12562708
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.
El Samad Y; Lanoix JP; Bennis Y; Diouf M; Saroufim C; Brunschweiler B; Rousseau F; Joseph C; Hamdad F; Ait Amer Meziane M; Routier S; Schmit JL
Antimicrob Agents Chemother; 2016 Oct; 60(10):6365-8. PubMed ID: 27458228
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous teicoplanin in staphylococcal bone and joint infections.
Destrem AL; Valour F; Ronde-Ousteau C; Gaudias J; Rogeaux O; Ferry T; Forestier E
Med Mal Infect; 2020 Feb; 50(1):83-86. PubMed ID: 31694793
[TBL] [Abstract][Full Text] [Related]
12. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
[TBL] [Abstract][Full Text] [Related]
13. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
14. In-vitro activity of teicoplanin and ceftriaxone in combination against pathogens involved in paediatric bone and joint infections.
Lhopital S; Bonacorsi S; Doit C; Sandin A; Bingen E
J Antimicrob Chemother; 1996 Oct; 38(4):713-8. PubMed ID: 8937966
[TBL] [Abstract][Full Text] [Related]
15. No change in the distribution of types and antibiotic resistance in clinical Staphylococcus aureus isolates from orthopaedic patients during a period of 12 years.
Aamot HV; Stavem K; Skråmm I
Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1833-7. PubMed ID: 26076750
[TBL] [Abstract][Full Text] [Related]
16. [Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)].
Grimprel E; Lorrot M; Haas H; Pinquier D; Parez N; Ferroni A; Cohen R;
Arch Pediatr; 2008 Oct; 15 Suppl 2():S74-80. PubMed ID: 19000859
[TBL] [Abstract][Full Text] [Related]
17. Fusidic acid in bone and joint infections.
Atkins B; Gottlieb T
Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S79-93. PubMed ID: 10528790
[TBL] [Abstract][Full Text] [Related]
18. [Osteoarticular infections: clinical studies].
Grimprel E; Lorrot M; Haas H; Pinquier D; Parez N; Ferroni A; Cohen R
Arch Pediatr; 2008 Oct; 15 Suppl 2():S68-73. PubMed ID: 19000858
[TBL] [Abstract][Full Text] [Related]
19. Linezolid therapy of bloodborne teicoplanin-resistant Staphylococcus haemolyticus.
Mohammedi I; Malhière S; Robert D; Charveriat MA; Etienne J
Infection; 2006 Oct; 34(5):292-3. PubMed ID: 17033757
[No Abstract] [Full Text] [Related]
20. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence.
Falagas ME; Giannopoulou KP; Ntziora F; Papagelopoulos PJ
Int J Antimicrob Agents; 2007 Sep; 30(3):202-9. PubMed ID: 17459668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
